Literature DB >> 29390929

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Siyang Leng1, Suzanne Lentzsch1,2, Yanhan Shen3, Wei-Yann Tsai3, Jason Dennis Wright2,4,5, Dawn Lauryn Hershman1,2,4, Alfred I Neugut1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29390929      PMCID： PMC6072618          DOI： 10.1080/10428194.2018.1429605

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  13 in total

Review 1.  Methods for evaluation of medication adherence and persistence using automated databases.

Authors:  Susan E Andrade; Kristijan H Kahler; Feride Frech; K Arnold Chan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

2.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

3.  Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

Authors:  Cecilie Blimark; Erik Holmberg; Ulf-Henrik Mellqvist; Ola Landgren; Magnus Björkholm; Malin Hultcrantz; Christian Kjellander; Ingemar Turesson; Sigurdur Y Kristinsson
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

4.  Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

Authors:  Abhisek Swaika; Aneel Paulus; Kena C Miller; Taimur Sher; Nikolaos G Almyroudis; Donna Ball; Margaret Wood; Aisha Masood; Kelvin Lee; Asher A Chanan-Khan
Journal:  J Support Oncol       Date:  2012-01-04

Review 5.  International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

Authors:  A Palumbo; O Sezer; R Kyle; J S Miguel; R Z Orlowski; P Moreau; R Niesvizky; G Morgan; R Comenzo; P Sonneveld; S Kumar; R Hajek; S Giralt; S Bringhen; K C Anderson; P G Richardson; M Cavo; F Davies; J Bladé; H Einsele; M A Dimopoulos; A Spencer; A Dispenzieri; T Reiman; K Shimizu; J H Lee; M Attal; M Boccadoro; M Mateos; W Chen; H Ludwig; D Joshua; J Chim; V Hungria; I Turesson; B G M Durie; S Lonial
Journal:  Leukemia       Date:  2009-06-04       Impact factor: 11.528

6.  Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.

Authors:  Eric Vickrey; Sharon Allen; Jayesh Mehta; Seema Singhal
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

7.  Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Authors:  Martin Kropff; Guido Bisping; Elke Schuck; Peter Liebisch; Nicola Lang; Markus Hentrich; Tobias Dechow; Nicolaus Kröger; Hans Salwender; Bernd Metzner; Orhan Sezer; Monika Engelhardt; Hans-Heinrich Wolf; Hermann Einsele; Sarah Volpert; Achim Heinecke; Wolfgang E Berdel; Joachim Kienast
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

8.  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Authors:  Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

9.  Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Authors:  Ji-Won Kim; Chang-Ki Min; Yeung-Chul Mun; Yong Park; Byung Soo Kim; Seung-Hyun Nam; Youngil Koh; Ji-Hyun Kwon; Pyoeng Gyun Choe; Wan Beom Park; Inho Kim
Journal:  J Clin Virol       Date:  2015-10-24       Impact factor: 3.168

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245
View more
  3 in total

Review 1.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

2.  Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.

Authors:  Qiaolin Zhou; Fang Xu; Jingjing Wen; Jing Yue; Ya Zhang; Jing Su; Yiping Liu
Journal:  Clin Exp Med       Date:  2022-09-12       Impact factor: 5.057

3.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.